{
    "title": "A bill to amend the Federal Food, Drug, and Cosmetic Act to provide the Food and Drug Administration with improved capacity to prevent drug shortages.",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Preserving Access to Life-Saving \nMedications Act''.\n\nSEC. 2. DRUG SHORTAGES.\n\n    (a) Expansion of Notification Requirement Regarding Potential \nShortages of Prescription Drugs.--Section 506C of the Federal Food, \nDrug, and Cosmetic Act (21 U.S.C. 356c) is amended--\n            (1) in the section heading, by striking ``discontinuance of \n        a life saving product'' and inserting ``discontinuance or \n        interruption of the manufacture of a prescription drug''; and\n            (2) by amending subsection (a) to read as follows:\n    ``(a) In General.--\n            ``(1) Definition.--In this section, the terms `drug \n        shortage' and `shortage', when used with respect to a drug, \n        mean a period of time when the total supply of all versions of \n        a drug available at the user level will not meet the current \n        demand for the drug at the user level.\n            ``(2) Notification.--A manufacturer of a drug described in \n        paragraph (3) shall notify the Secretary of a discontinuance, \n        interruption, or other adjustment of the manufacture of the \n        drug that would likely result in a shortage of such drug--\n                    ``(A) in the case of a discontinuance or planned \n                interruption or adjustment, at least 6 months prior to \n                the date of such discontinuance or planned interruption \n                or adjustment; and\n                    ``(B) in the case of any other interruption or \n                adjustment, as soon as practicable after becoming aware \n                of such interruption or adjustment.\n            ``(3) Drugs described.--A drug described in this paragraph \n        is a drug--\n                    ``(A) for which an application has been approved \n                under section 505(b) or 505(j);\n                    ``(B) that is described in section 503(b)(1); and\n                    ``(C) that is not a product that was originally \n                derived from human tissue and was replaced by a \n                recombinant product.\n            ``(4) Types of adjustments.--An adjustment for which a \n        manufacturer shall submit a notification under paragraph (2) \n        includes--\n                    ``(A) adjustments related to the supply of raw \n                materials, including active pharmaceutical ingredients;\n                    ``(B) adjustments to production capabilities;\n                    ``(C) business decisions that may affect the \n                manufacture of the drug, such as mergers, \n                discontinuations, and a change in production output; \n                and\n                    ``(D) other adjustments as determined appropriate \n                by the Secretary.\n            ``(5) Modification of time frames.--The Secretary may \n        adjust the required time frame under paragraph (2) as \n        determined appropriate by the Secretary based on--\n                    ``(A) the type of interruption or adjustment at \n                issue; and\n                    ``(B) any other factor, as determined by the \n                Secretary.\n            ``(6) Enforcement.--Not later than 180 days after the date \n        of enactment of this section, the Secretary shall promulgate \n        regulations establishing a schedule of civil monetary penalties \n        for failure to submit a notification as required under this \n        subsection.''.\n    (b) Confidentiality of Information.--Section 506C(c) of the Federal \nFood, Drug, and Cosmetic Act (21 U.S.C. 356c(c)) is amended to read as \nfollows:\n    ``(c) Confidentiality of Information.--The Secretary shall ensure \nthe confidentiality of proprietary information submitted in a \nnotification under subsection (a).''.\n    (c) Public Notification.--Section 506C of the Federal Food, Drug, \nand Cosmetic Act (21 U.S.C. 356c) is amended by adding at the end the \nfollowing:\n    ``(d) Public Notification.--\n            ``(1) Notification of shortages.--The Secretary shall \n        publish information on the types of adjustments for which a \n        notification is required under subsection (a)(4) and on actual \n        drug shortages on the Internet Web site of the Food and Drug \n        Administration and, to the maximum extent practicable, \n        distribute such information to appropriate health care provider \n        and patient organizations.\n            ``(2) Identification and notification of drugs vulnerable \n        to drug shortage.--\n                    ``(A) In general.--The Secretary shall implement \n                evidence-based criteria for identifying drugs that may \n                be vulnerable to a drug shortage. Such criteria shall \n                be based on--\n                            ``(i) the number of manufacturers of the \n                        drug;\n                            ``(ii) the sources of raw material or \n                        active pharmaceutical ingredients;\n                            ``(iii) the supply chain characteristics, \n                        such as production complexities; and\n                            ``(iv) the availability of therapeutic \n                        alternatives.\n                    ``(B) Notification.--If the Secretary determines \n                using the criteria under subparagraph (A) that a drug \n                may be vulnerable to a drug shortage, the Secretary \n                shall notify the manufacturer of the drug of such \n                determination and of the collaboration described under \n                paragraph (3).\n            ``(3) Continuity of operations plans.--The Secretary shall \n        collaborate with manufacturers of drugs identified pursuant to \n        paragraph (2) to establish and improve continuity of operations \n        plans with respect to medically necessary drugs, as defined by \n        the Secretary, so that such plans include a process for \n        addressing drug shortages.''.\n\nSEC. 3. MANUFACTURER REVIEW.\n\n    Section 510(h) of the Federal Food, Drug, and Cosmetic Act (21 \nU.S.C. 360(h)) is amended--\n            (1) by striking ``(h)'' and inserting ``(h)(1)''; and\n            (2) by inserting at the end the following:\n    ``(2)(A) If an establishment registered with the Secretary pursuant \nto this section is subject to a reinspection due to failure to comply \nwith a requirement of this Act, the Secretary shall conduct such \nreinspection not later than 90 days after the establishment certifies \nto the Secretary that the establishment has corrected the reason for \nsuch failure.\n    ``(B) The Secretary shall prioritize reinspections described in \nsubparagraph (A) based on whether the establishment involved \nmanufactures, propagates, compounds, or processes a drug involved in a \ndrug shortage (as defined in section 506C).''.\n\nSEC. 4. REPORTS TO CONGRESS.\n\n    Not later than 1 year after the date of enactment of this Act, and \non an annual basis thereafter, the Secretary of Health and Human \nServices shall submit to Congress a report that describes the actions \ntaken by such Secretary during the previous 1-year period to address \ndrug shortages through all aspects of the prescription drug supply \nchain."
}